# Serum Concentration of Adalimumab as a Predictive Factor of Clinical Outcomes in Rheumatoid Arthritis (AFORA)

> **NCT01382160** · PHASE4 · COMPLETED · sponsor: **University Hospital, Tours** · enrollment: 69 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **BIOLOGICAL:** adalimumab

## Key facts

- **NCT ID:** NCT01382160
- **Lead sponsor:** University Hospital, Tours
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2013-07
- **Final completion:** 2013-07
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2025-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01382160

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01382160, "Serum Concentration of Adalimumab as a Predictive Factor of Clinical Outcomes in Rheumatoid Arthritis (AFORA)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01382160. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*